摘要
纳米医学涉及用于治疗和诊断目的纳米颗粒的应用。在过去的二十年中,越来越多的纳米药物已获得监管部门的批准,并表现出良好的临床应用前景。因此,为了实现生物相容性以及体现其活性,对纳米颗粒的安全性进行评估显得十分重要。然而,由于纳米医学领域包括各种不同材料制成的纳米颗粒,这就并不一定要去强调纳米粒子的安全性。事实上,一些纳米治疗目前正在审批,如阿霉素和白蛋白结合型紫杉醇,尽管它们与比它们的小分子会表现出更小的副作用,其他纳米粒子(如金属和碳基颗粒)往往显示毒性。然而,如果靶点选择可以实现,某些纳米药物的危险性就可以应用于病变组织的消融。本文讨论了分子、细胞、器官和免疫系统的毒性机制,这可以通过纳米粒子的亚群来观测。本文对通过表面修饰和免疫调节剂预处理来提高纳米粒子的安全性的方法就行了讨论。此外,本文对纳米粒子的安全性的重要考察因素进行了概括。对于临床应用,不需要对纳米药物的审批进行更严格的规定。相反,应调整安全评价分析,使其更适于工程纳米粒子。
关键词: 纳米药物,纳米颗粒,纳米安全性,纳米毒性,安全性,毒性。
图形摘要
Current Drug Targets
Title:Safety of Nanoparticles in Medicine
Volume: 16 Issue: 14
Author(s): Joy Wolfram, Motao Zhu, Yong Yang, Jianliang Shen, Emanuela Gentile, Donatella Paolino and Massimo Fresta, Guangjun Nie, Chunying Chen, Haifa Shen, Mauro Ferrari and Yuliang Zhao
Affiliation:
关键词: 纳米药物,纳米颗粒,纳米安全性,纳米毒性,安全性,毒性。
摘要: Nanomedicine involves the use of nanoparticles for therapeutic and diagnostic purposes. During the past two decades, a growing number of nanomedicines have received regulatory approval and many more show promise for future clinical translation. In this context, it is important to evaluate the safety of nanoparticles in order to achieve biocompatibility and desired activity. However, it is unwarranted to make generalized statements regarding the safety of nanoparticles, since the field of nanomedicine comprises a multitude of different manufactured nanoparticles made from various materials. Indeed, several nanotherapeutics that are currently approved, such as Doxil and Abraxane, exhibit fewer side effects than their small molecule counterparts, while other nanoparticles (e.g. metallic and carbon-based particles) tend to display toxicity. However, the hazardous nature of certain nanomedicines could be exploited for the ablation of diseased tissue, if selective targeting can be achieved. This review discusses the mechanisms for molecular, cellular, organ, and immune system toxicity, which can be observed with a subset of nanoparticles. Strategies for improving the safety of nanoparticles by surface modification and pretreatment with immunomodulators are also discussed. Additionally, important considerations for nanoparticle safety assessment are reviewed. In regards to clinical application, stricter regulations for the approval of nanomedicines might not be required. Rather, safety evaluation assays should be adjusted to be more appropriate for engineered nanoparticles.
Export Options
About this article
Cite this article as:
Joy Wolfram, Motao Zhu, Yong Yang, Jianliang Shen, Emanuela Gentile, Donatella Paolino and Massimo Fresta, Guangjun Nie, Chunying Chen, Haifa Shen, Mauro Ferrari and Yuliang Zhao , Safety of Nanoparticles in Medicine , Current Drug Targets 2015; 16 (14) . https://dx.doi.org/10.2174/1389450115666140804124808
DOI https://dx.doi.org/10.2174/1389450115666140804124808 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Angiotensin, The Hormone to be Blocked by Antithypertensive Drugs, and Perhaps Why They Dont Work
Current Vascular Pharmacology A Critical Review on the Unexplored Therapeutic Treasure of Himalayan Ayurvedic Drug Daruharidra (<i>Berberis Aristata</i>)
Current Traditional Medicine Small Molecules in Treatment of Sepsis
Current Drug Targets Acute Kidney Injury in Pediatric Heart Failure
Current Cardiology Reviews Recent Advancements in Diagnosis and Therapy of Liver Cirrhosis
Current Drug Targets Targeting Malignancies with Disulfiram (Antabuse): Multidrug Resistance, Angiogenesis, and Proteasome
Current Cancer Drug Targets Drug-Induced Peripheral Neuropathy: Diagnosis and Management
Current Cancer Drug Targets Pharmacogenomics and Sepsis-Induced Renal Failure: Effects of β 2-Adrenoceptor Function on the Course of Sepsis
Current Pharmacogenomics and Personalized Medicine Adverse Reactions Induced by Minocycline: A Review of Literature
Current Drug Safety Influence of Dietary Substances on Intestinal Drug Metabolism and Transport
Current Drug Metabolism Pharmacology and Therapeutic Applications of Enediyne Antitumor Antibiotics
Current Molecular Pharmacology Glucocorticoid Measurements in Health and Disease - Metabolic Implications and the Potential of 24-h Urine Analyses
Mini-Reviews in Medicinal Chemistry Evaluation of Endothelial (dys)Function, Left Ventricular Structure and Function in Patients with Chronic Kidney Disease
Current Vascular Pharmacology Endocannabinoids and their Involvement in the Neurovascular System
Current Neurovascular Research Adrenal Insufficiency in Sepsis
Current Pharmaceutical Design Addiction Liability of Pharmacotherapeutic Interventions in Obesity
Current Pharmaceutical Design Ziconotide: Neuronal Calcium Channel Blocker for Treating Severe Chronic Pain
Current Medicinal Chemistry The Role of Toll-Like Receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: A New Promising Therapeutic Approach?
CNS & Neurological Disorders - Drug Targets Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes
Current Neuropharmacology Therapeutic Potential of Nitrate Esters of Commonly Used Drugs
Current Topics in Medicinal Chemistry